AstraZeneca Pharma gets CDSCO approval for Enhertu additional breast cancer indication

AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organization (CDSCO) to import and market Trastuzumab Deruxtecan (brand name Enhertu) for an additional indication. The drug is now approved for neoadjuvant treatment of adult patients with HER2-positive Stage II or III breast cancer, given before THP therapy (taxane, trastuzumab, and pertuzumab). This expands Enhertu's addressable market in India beyond its current approved uses, subject to any remaining statutory approvals before launch.